204 results
DEFM14A
IMGN
Immunogen, Inc.
2 Jan 24
Proxy related to merger
4:26pm
of a debt commitment letter.
On November 28, 2023, representatives of Party A informed representatives of Lazard that, while Party A remained highly … , and an executed debt commitment letter (the “Party B November 29 Proposal”). Among other changes, Party B’s revised merger agreement draft rejected any
PREM14A
IMGN
Immunogen, Inc.
21 Dec 23
Preliminary proxy related to merger
4:52pm
of a debt commitment letter.
On November 28, 2023, representatives of Party A informed representatives of Lazard that, while Party A remained highly … , and an executed debt commitment letter (the “Party B November 29 Proposal”). Among other changes, Party B’s revised merger agreement draft rejected any
DEFA14A
IMGN
Immunogen, Inc.
21 Dec 23
Additional proxy soliciting materials
3:54pm
. This commitment will extend for one year following the closing of the merger.
Is there an impact on our Employee Stock Purchase Plan (ESPP)? What happens … as employee benefits that are at least as favorable in the aggregate as those benefits provided at closing and that this commitment will extend for the period
DEFA14A
IMGN
Immunogen, Inc.
30 Nov 23
Additional proxy soliciting materials
4:08pm
and our future potential to deliver more good days to people living with cancer.
This transaction is the culmination of our 40-year commitment … as the benefits provided to you at closing. This commitment will extend for the period of one year following the closing of the merger.
All employment
DEFA14A
EX-2.1
IMGN
Immunogen, Inc.
30 Nov 23
Additional proxy soliciting materials
4:07pm
the HSR Act, and any commitment by the parties (if any) not to consummate the Merger before a certain date under a timing agreement with a Governmental Body … , purchase order, license, sublicense, commitment or undertaking of any nature, which, in each case, is legally binding upon a party or on any of its
DEFA14A
EX-99.1
3kxd6xnty
30 Nov 23
Additional proxy soliciting materials
4:07pm
8-K
EX-2.1
7rtho48e 95lbuy7xyz
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
8-K
EX-99.1
bb5x61wlkw8cwh5edvzq
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
8-K
EX-99.1
rcw 2ywtgigr91
2 Nov 23
ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results
6:35am
8-K
EX-99.1
w0v3l01hn xgiocr
18 Sep 23
ImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial Officer
6:35am
8-K
EX-99.1
0eq0n7ll34u0u
31 Jul 23
ImmunoGen Reports Recent Progress and Second Quarter 2023 Financial Results
6:40am
8-K
EX-1.1
xdrjd02
5 May 23
Entry into a Material Definitive Agreement
5:15pm
424B5
qwz3zzfhrfq 48nmmmk
5 May 23
Prospectus supplement for primary offering
4:49pm
424B5
9nvpf4 z293yo
3 May 23
Prospectus supplement for primary offering
4:05pm
8-K
EX-99.1
t4lr9 bvp9
3 May 23
ELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian Cancer
6:35am
8-K
EX-99.1
3bw3kza1axht uo8oxe4
28 Apr 23
ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results
6:36am